Immix Biopharma Reports 95% Complete Response Rate in Phase 2 NEXICART-2 Trial for AL Amyloidosis

On May 21, 2026, Immix Biopharma announced positive interim data from its Phase 2 NEXICART-2 clinical trial evaluating NXC-201, a BCMA-targeted CAR-T cell therapy, for relapsed/refractory light chain (AL) Amyloidosis. The company reported that all four MRD-negative patients previously identified at ASH 2025 have now converted to complete response (CR). Among the first 20 patients in the trial, the CR rate has reached 95% (19/20). Notably, all CRs were achieved within one year of dosing, and no relapses have been observed to date in patients who reached CR. Safety data remains consistent with previous reports. Based on these results, ImmixBio plans to initiate a randomized Phase 3 trial for newly diagnosed AL Amyloidosis in H1 2027. The company expects to present one-year follow-up data by the end of March 2027 to support a BLA submission and subsequent commercial launch. NXC-201 currently holds Breakthrough Therapy and Orphan Drug designations from the FDA.